$NTLA News

Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17

Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of Medicine

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Intellia Therapeutics To Highlight Data From Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema In Late-Breaking Oral Presentation At EAACI Annual Congress 2026

Intellia Therapeutics Announces That Data From The Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema Will Be Presented At The European Academy Of Allergy & Clinical Immunology Annual Congress 2026

Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Bernstein Maintains Market Perform on Intellia Therapeutics, Raises Price Target to $17

HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Lowers Price Target to $25

Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $49

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates